Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $20.00 | Outperform | Raymond James |
| 7/14/2023 | Overweight | Piper Sandler | |
| 6/30/2023 | $2.00 → $10.00 | Hold → Buy | Stifel |
| 6/28/2023 | $11.00 | Neutral → Buy | H.C. Wainwright |
| 6/27/2023 | $10.00 | Neutral → Outperform | Wedbush |
| 3/29/2022 | Outperform → Neutral | Wedbush | |
| 3/22/2022 | Buy → Neutral | H.C. Wainwright | |
| 9/30/2021 | $10.00 | Hold | Stifel |
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as of September 30, 2024; expected to be sufficient to fund operations into Q2 of 2026 CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-st
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024 Webcasts will be available at the start of the presentations on the investor relations section
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026. BDTX-1535 has demonstrated robust Phase 2 clinical activity acros
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i
SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00
Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight
Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously
10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
Piper Sandler analyst Joseph Catanzaro maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and maintains $12 price target.
Gainers Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.61% to $2.75. The company's market cap stands at $26.0 million. Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 20.26% to $3.03. The company's market cap stands at $35.5 million. Kronos Bio (NASDAQ:KRON) shares increased by 16.71% to $1.11. The market value of their outstanding shares is at $66.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) shares increased by 15.72% to $5.91. The market value of their outstanding shares is at $332.7 million. Streamline Health Solns (NASDAQ:ST
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir